Skip to content

Clinical observation trial to explore the comorbidity biological basis of chronic heart failure combined with depression with qi stagnation blood stasis and toxic damage syndrome from the heart-intestine-brain axis.

Study on the comorbidity biological basis and corresponding treatment mechanism of chronic heart failure combined with depression with qi stagnation blood stasis and toxin damage syndrome from the heart-gut-brain axis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2024000640
Enrollment
Unknown
Registered
2024-11-03
Start date
2024-11-11
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic heart failure combined with depression

Interventions

Healthy volunteer group:null
Chronic heart failure combined with depression group (observation group):null
Chronic heart failure without depression group (control group):null

Sponsors

Institute of Basic Theory for Traditional Chinese Medicine China Academy of Chinese Medical Sciences Beijing China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) The age of the subjects ranged from 50 to 75 years; (2) According to the diagnostic criteria of chronic heart failure chronic heart failure was diagnosed for more than 3 months; (3) The clinical symptoms were in line with the "China heart failure diagnosis and treatment guidelines 2024": the symptoms were dyspnea fatigue and fluid retention (pulmonary congestion systemic congestion and peripheral edema). Because the compensatory degree of heart failure and the affected ventricle are different the symptoms and signs of patients with heart failure have great individual differences and patients with well compensated heart failure can be asymptomatic and physical signs; (4) NYHA cardiac function classification ? - ?; (5) Left ventricular ejection fraction (LVEF) < 50% (including hfref with reduced ejection fraction hfimpef with improved ejection fraction hfmref with mildly reduced ejection fraction and HFPEF with preserved ejection fraction); (6) Serum N-terminal pro-B-type natriuretic peptide (NT proBNP) = 900 pg / ml or B-type natriuretic peptide (BNP) = 450pg / ml; (7) Non diabetic patients; (8) Not taking antidepressants; (9) Voluntarily participate in this research and sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients after coronary artery bypass grafting; (2) Patients with pacemaker implantation; (3) Patients with blurred consciousness; (4) The patient had chest wall trauma; (5) The patient had pneumothorax; (6) The patient had hemorrhagic shock; (7) Patients need ventilator treatment;

Design outcomes

Primary

MeasureTime frame
Detection of intestinal flora;Transcriptomics target detection;

Countries

China

Contacts

Public ContactLI Yubo

Institute of Basic Theory for Traditional Chinese Medicine China Academy of Chinese Medical Sciences Beijing China

liyb@ibtcm.ac.cn+86 15811221143

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026